• ProQR Therapeutics posted a Q1 net loss of € 13.4 million, or € 0.13 per diluted share, widening from € 10.1 million, or € 0.10 per diluted share, a year earlier.
• R&D costs edged down to € 11.8 million from € 12.3 million, while general and administrative costs climbed to € 3.9 million from € 3.2 million.
• Cash and cash equivalents fell to € 81.1 million at March 31, 2026 from € 92.4 million at year-end 2025; net cash used in operating activities was € 11.1 million versus € 15.8 million a year earlier.
• AX-0810 Phase 1 target engagement data in healthy volunteers remains on track for Q2 2026, with biliary atresia selected as the initial Phase 2 indication and initial pediatric China IIT data targeted for H1 2027.
• Pipeline plans call for AX-0811 CTA filing in mid-2026 with initial data by year-end 2026, while AX-0422 CTA filing is expected in early 2027 with initial data in H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-058980), on May 12, 2026, and is solely responsible for the information contained therein.